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 has recently disputed the recommendations of several international guidelines on the 
use of lithium in bipolar depression. In his scrutiny, the author points to three main errors that 
seem to have affected systematically ten international guidelines, namely the Woozle effect 
(evidence by citation), reference inflation (inappropriate citation of pivotal, generally old, 
studies) and belief perseverance (inability to modify evidence-base recommendations despite 
the presence of contrary data). We concur with the author that the evidence supporting the 
effectiveness of lithium in acute bipolar depression, and to a lesser degree also in major 
depressive episodes, remains inadequate.
2,3
 A different matter is, in our opinion, to label 
guidelines recommendations as inaccurate or biased, even if, as the author stated, no 
deceptive intentions were present. As Kelly points out, lithium might have been the most 
studied drug in bipolar disorder, but its effect in acute bipolar depression remains largely 
untested. However, some comments could be made: 1) The author claims that these 
phenomena interfere with our understanding of the scarce evidence, but no guideline 
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have tried to formulate recommendations placing the available evidence, even if limited, into 
a real-world clinical context. Illustrative of this is the explanation formulated in the Canadian 
Network for Mood and Anxiety Treatments (CANMAT) guideline concerning the possible 
influence of low serum lithium levels on the scarce therapeutic efficacy in the only large 
double blind placebo controlled trial conducted to date in bipolar depression.
4
 2) We need to 
differentiate between evidence and recommendation. This is especially relevant in a situation 
where there are no easy alternatives. Even if aware of the weak evidence for the acute 
antidepressant effect of lithium, experts panels might recommend it as first-line treatment for 
bipolar disorder in depressive phases for its effect in preventing further manic, hypomanic, or 
depressive recurrences. 3) The well-demonstrated antisuicidal effects of lithium justify its use 
in acute depressive episodes, even in non-bipolar disorder subjects. 4) Lithium augmentation 
of antidepressants in treatment-resistant depressive episodes has been established as an 
effective therapeutic option.
5
 This effect may be associated with the presence of mixed 
features in treatment-resistant depressions. 5) Rather than indicating a methodological 
problem, the apparent inconsistencies found in the guidelines by Kelly highlight the absence 
of valid alternative treatments for bipolar disorder. 
In conclusion, we reckon that the guideline recommendations for using lithium in bipolar 
depression should not be chosen as case in point of unintentional, biased, assessment of the 
literature. On the contrary, they emphasize the surprisingly large gap in the knowledge on the 
effectiveness of lithium in depressive phases despite the extensive use of this mood stabilizer 
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